Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis

Clinical and Experimental Immunology

Volumn 175, Issue 2, 2014, Pages 208-214

  Migita, K ^a   Izumi, Y ^a   Jiuchi, Y ^a   Kozuru, H ^a   Kawahara, C ^a   Izumi, M ^a   Sakai, T ^a   Nakamura, M ^a   Motokawa, S ^a   Nakamura, T ^b   Kawakami, A ^c  

^a NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^b Kumamoto Shinto General Hospital   (Japan)

^c NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Interleukin 6; Janus kinase; Rheumatoid arthritis; Serum amyloid A; Tofacitinib

Indexed keywords

INTERLEUKIN 6; JANUS KINASE; METHOTREXATE; PLACEBO; SERUM AMYLOID A; TOFACITINIB;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG EFFECT; FEMALE; HUMAN; JAPANESE; MALE; MIDDLE AGED; MONOTHERAPY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS;

INTERLEUKIN-6; JANUS KINASE; RHEUMATOID ARTHRITIS; SERUM AMYLOID A; TOFACITINIB;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIMETABOLITES, ANTINEOPLASTIC; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; DOWN-REGULATION; FEMALE; HUMANS; INTERLEUKIN-6; JANUS KINASE 3; MALE; METHOTREXATE; MIDDLE AGED; PIPERIDINES; PLACEBOS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RECEPTORS, INTERLEUKIN-6; SERUM AMYLOID A PROTEIN;

EID: 84891595629     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12234     Document Type: Article

References (29)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376:1094-1108.
2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365:2205-2219.
3. Buch MH, Emery P. New therapies in the management of rheumatoid arthritis. Curr Opin Rheumatol 2011; 23:245-251.
4. Choy EH, Kavanaugh AF, Jones SA. The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol 2013; 9:154-163.
5. Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ. Therapeutic targeting of Janus kinases. Immunol Rev 2008; 223:132-142.
6. Tanaka Y, Maeshima K, Yamaoka K. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis. Ann Rheum Dis 2012; 71:i70-74.
7. Kremer JM, Bloom BJ, Breedveld FC etal. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690, 550 versus placebo. Arthritis Rheum 2009; 60:1895-1905.
8. Coombs JH, Bloom BJ, Breedveld FC etal. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690, 550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2010; 69:413-416.
9. Fleischmann R, Kremer J, Cush J etal. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367:495-507.
10. Kremer JM, Cohen S, Wilkinson BE etal. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690, 550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012; 64:970-981.
11. Fleischmann R, Cutolo M, Genovese MC etal. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690, 550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012; 64:617-629.
12. Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 1996; 26:427-435.
13. Cunnane G, Grehan S, Geoghegan S etal. Serum amyloid A in the assessment of early inflammatory arthritis. J Rheumatol 2000; 27:58-63.
14. Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 2006; 54:2997-3000.
15. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998; 16:293-322.
16. Hagihara K, Nishikawa T, Sugamata Y etal. Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression. Genes Cells 2005; 10:1051-1063.
17. Migita K, Koga T, Komori A etal. Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium. J Rheumatol 2011; 38:2309-2317.
18. Migita K, Komori A, Torigoshi T etal. CP690, 550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes. Arthritis Res Ther 2011; 13:R72.
19. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun 2004; 314:363-369.
20. Connolly M, Mullan RH, McCormick J etal. Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. Arthritis Rheum 2012; 64:1035-1045.
21. van Leeuwen MA, Westra J, Limburg PC, van Riel PL, van Rijswijk MH. Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study. Ann Rheum Dis 1995; 54:674-677.
22. Shimamoto K, Ito T, Ozaki Y etal. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. J Rheumatol 2013; 40:1074-1081.
23. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009; 228:273-287.
24. Choe JY, Park KY, Park SH, Lee SI, Kim SK. Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes. Arthritis Res Ther 2013; 15:R26.
25. Rosengren S, Corr M, Firestein GS, Boyle DL. The JAK inhibitor CP-690, 550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis 2012; 71:440-447.
26. Schoels MM, van der Heijde D, Breedveld FC etal. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis 2013; 72:583-589.
27. Maeshima K, Yamaoka K, Kubo S etal. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells. Arthritis Rheum 2012; 64:1790-1798.
28. Yarilina A, Xu K, Chan C, Ivashkiv LB. Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum 2012; 64:3856-3866.
29. Lin TH, Hegen M, Quadros E etal. Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice. Arthritis Rheum 2010; 62:2283-2293.